Patents by Inventor Yideul JEONG

Yideul JEONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition for preventing or treating cancers comprising dendritic cells with Dab2 gene silenced
    Patent number: 9566304
    Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 14, 2017
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Yong-Soo Bae, Se Eun Byeon, Selim Ahmed, Yideul Jeong
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCERS COMPRISING DENDRITIC CELLS WITH DAB2 GENE SILENCED
    Publication number: 20150283176
    Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.
    Type: Application
    Filed: November 7, 2014
    Publication date: October 8, 2015
    Applicant: Research & Business Foundation Sungkyunkwan University
    Inventors: Yong-Soo BAE, Se Eun BYEON, Selim AHMED, Yideul JEONG